The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review

World Bank Group. Health expenditure, total (% of GDP)|Data. https://data.worldbank.org/indicator/SH.XPD.TOTL.ZS . Accessed 14 Sept 2017.

Vogler S, Zimmermann N, Leopold C, de Joncheere K. Pharmaceutical policies in European countries in response to the global financial crisis. South Med Rev. 2011;4(2):69–79. https://doi.org/10.5655/smr.v4i2.1004 .

Health at a Glance 2015. OECD Publishing; 2015. https://doi.org/10.1787/health_glance-2015-en .

Cameron A, Mantel-Teeuwisse AK, Leufkens HGM, Laing RO. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved? Value Health. 2012;15(5):664–73. https://doi.org/10.1016/j.jval.2012.04.004 .

Liberman JN, Roebuck MC. Prescription drug costs and the generic dispensing ratio. J Manag Care Pharm. 2010;16(7):502–6. https://doi.org/10.18553/jmcp.2010.16.7.502 .

Lakdawalla DN, Philipson T, Wang R. Intellectual property and marketing. 2007. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=1089045&rec=1&srcabs=328692&alg=7&pos=10 . Accessed 14 Sept 2017.

Handoo S, Arora V, Khera D, Nandi PK, Sahu SK. A comprehensive study on regulatory requirements for development and filing of generic drugs globally. Int J Pharm Investig. 2012;2(3):99–105. https://doi.org/10.4103/2230-973X.104392 .

Kelton CML, Chang LV, Guo JJ, et al. Firm- and drug-specific patterns of generic drug payments by US medicaid programs: 1991–2008. Appl Health Econ Health Policy. 2014;12(2):165–77. https://doi.org/10.1007/s40258-014-0083-z .

Clarke PM, Fitzgerald EM. Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia. Med J Aust. 2010;192(11):633–636. http://www.ncbi.nlm.nih.gov/pubmed/20528715 . Accessed 14 Sept 2017.

Berndt ER, Mortimer R, Bhattacharjya A, Parece A, Tuttle E. Authorized generic drugs, price competition and consumers’ welfare. Health Aff. 2007;26(3):790–9. https://doi.org/10.1377/hlthaff.26.3.790 .

Hong SH, Shepherd MD, Scoones D, Wan TTH. Product-line extensions and pricing strategies of brand-name drugs facing patent expiration. J Manag Care Pharm. 2005;11(9):746–54. https://doi.org/10.18553/jmcp.2005.11.9.746 .

Boersma C, Klok RM, Bos JM, et al. Drug costs developments after patent expiry of enalapril, fluoxetine and ranitidine: a study conducted for the Netherlands. Appl Health Econ Health Policy. 2005;4(3):191–196. http://www.ncbi.nlm.nih.gov/pubmed/16309337 . Accessed 14 Sept 2017.

Magazzini L, Pammolli F, Riccaboni M. Dynamic competition in pharmaceuticals. Eur J Heal Econ Former HEPAC. 2004;5(2):175–82. https://doi.org/10.1007/s10198-003-0218-x .

Lexchin J. The effect of generic competition on the price of brand-name drugs. Health Policy (New York). 2004;68(1):47–54. https://doi.org/10.1016/j.healthpol.2003.07.007 .

Suh DC, Manning WG, Schondelmeyer S, Hadsall RS, Hadsall RS. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry. Health Serv Res. 2000;35(2):529–547. http://www.ncbi.nlm.nih.gov/pubmed/10857475 . Accessed 14 Sept 2017.

Grabowski H, Long G, Mortimer R. Recent trends in brand-name and generic drug competition. J Med Econ. 2014;17(3):207–14. https://doi.org/10.3111/13696998.2013.873723 .

Grabowski H, Long G, Mortimer R, Boyo A. Updated trends in US brand-name and generic drug competition. J Med Econ. 2016;19(9):836–44. https://doi.org/10.1080/13696998.2016.1176578 .

Berndt ER, Aitken ML. Brand loyalty, generic entry and price competition in pharmaceuticals in the quarter century after the 1984 Waxman-Hatch legislation. Int J Econ Bus. 2011;18(2):177–201. http://www.tandfonline.com/loi/cijb20 .

Kanavos P, Costa-Font J, Seeley E. Competition in off-patent drug markets: issues, regulation and evidence. Econ Policy. 2008;23(55):499. http://onlinelibrary.wiley.com/journal/10.1111/%28ISSN%291468-0327/issues .

Puig-Junoy J. Do higher-priced generic medicines enjoy a competitive advantage under reference pricing? Appl Health Econ Health Policy. 2012;10(6):441–51. https://doi.org/10.2165/11633810-000000000-00000 .

Saha A, Grabowski H, Birnbaum H, Greenberg P, Bizan O. Generic competition in the US pharmaceutical industry. Int J Econ Bus. 2006;13(1):15–38. https://doi.org/10.1080/13571510500519905 .

Wiggins SN, Maness R. Price competition in pharmaceuticals: The case of anti-infectives. Econ Inq. 2004;42(2):247–63. https://doi.org/10.1093/ei/cbh058 .

Vandoros S, Kanavos P. The generics paradox revisited: empirical evidence from regulated markets. Appl Econ. 2013;45(22):3230–9. https://doi.org/10.1080/00036846.2012.703313 .

Grabowski HG, Ridley DB, Schulman KA. Entry and competition in generic biologics. Manag Decis Econ. 2007;28(4–5):439–51. https://doi.org/10.1002/mde.1352 .

Zorinstituut Nederland. Geneesmiddelen Horizonscan. https://www.horizonscangeneesmiddelen.nl/binaries/content/assets/horizonscan/gepublicatie-scan-1-september-2017-correctie.pdf . Published 2017. Accessed 15 Sept 2017.